<SEC-DOCUMENT>0001193125-24-236688.txt : 20241011
<SEC-HEADER>0001193125-24-236688.hdr.sgml : 20241011
<ACCEPTANCE-DATETIME>20241011153557
ACCESSION NUMBER:		0001193125-24-236688
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20241011
FILED AS OF DATE:		20241011
DATE AS OF CHANGE:		20241011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241367446

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d871391d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>46, avenue de
la Grande Arm&eacute;e, 75017 Paris, FRANCE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2024, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exhibit<br>No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d871391dex991.htm">Press Release dated October&nbsp;9, 2024: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d871391dex992.htm">Press Release dated October&nbsp;11, 2024: Sanofi in discussions to sell a controlling stake in Opella </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;11, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alexandra Roger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d871391dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-family:Verdana; font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g871391img01.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and
hospitalization in infants </I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana"><B>Paris, October</B><B></B><B>&nbsp;9, 2024</B>. Sanofi advances its ambition to protect all infants from respiratory
syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America&#146;s IDWeek 2024 annual meeting in Los Angeles, California, from October <FONT STYLE="white-space:nowrap">16-19,</FONT>
2024. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><B><I>Thomas Triomphe </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Verdana" ALIGN="justify">Executive Vice President, Vaccines, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; margin-right:7%; font-size:10pt; font-family:Georgia" ALIGN="justify"><I>&#147;The data featured at IDWeek from several national immunization programs will reinforce the proven efficacy
and favorable safety profile of Beyfortus against RSV disease and hospitalization in infants. In just the first year of implementation, Beyfortus has demonstrated high real-world effectiveness consistently exceeding 80%. In addition, Beyfortus
delivers this protection in the right dose for the right baby. We&#146;re proud to set a new standard with Beyfortus as the only approved and proven RSV protection for infants regardless of whether they are born before or during the RSV season, at
term or preterm, healthy or with underlying conditions.&#148; </I></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Beyfortus&nbsp;doses continue to be shipped to meet global commitments ahead of
the 2024-2025 RSV season. A second manufacturing filling line has been approved by regulatory authorities in the US, Canada, and Europe&nbsp;and represents the majority of our supply for the 2024-2025 season. A third filling line, expected to
provide additional doses for the 2024-2025 season, is approved by the European Medicines Agency and under review by the US Food and Drug Administration. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Beyfortus and RSV data at IDWeek 2024 </I></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Thursday, October</B><B></B><B>&nbsp;17, <FONT STYLE="white-space:nowrap">12:15-1:30</FONT> pm PT:</B> RSV
Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact (Sanofi, presented by Oliver Martyn, MPH, Poster# <FONT STYLE="white-space:nowrap">P-631)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Thursday, October</B><B></B><B>&nbsp;17, <FONT STYLE="white-space:nowrap">12:15-1:30</FONT> pm PT:
</B>Implementation and Uptake of Nirsevimab within Nemours Children&#146;s Health Delaware Healthcare System (independent study by Nemours Children&#146;s Health Delaware, presented by Sara Mann, Poster#
<FONT STYLE="white-space:nowrap">P-633)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Thursday, October</B><B></B><B>&nbsp;17, <FONT STYLE="white-space:nowrap">1:15-2:00</FONT> pm PT</B> Preventing RSV
Lower Respiratory Tract Disease in Infants: The First Year in Review (Sanofi, Learning Lounge event)<B> </B> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Thursday, October</B><B></B><B>&nbsp;17, <FONT STYLE="white-space:nowrap">1:45-3:00</FONT> pm PT:</B> Universal
Immunization Strategy Against Respiratory Syncytial Virus (RSV) Prevention in Chile with Nirsevimab during the 2024 Winter Season: First Southern Hemisphere Nationwide Effectiveness Data (independent study by University of Chile, presented by Juan
Pablo Torres-Torretti, MD, PhD, during the Late Breaker Abstract Session: Respiratory Viruses Across All Ages, #169). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Friday, October</B><B></B><B>&nbsp;18, <FONT STYLE="white-space:nowrap">12:15-1:30</FONT> pm PT:</B> Significant
Reduction in Disease Burden and a Shift in Clinical Diagnoses in Children Hospitalized with Respiratory Syncytial Virus (RSV) after Nirsevimab Implementation in Catalonia (Spain) (independent study presented by Anna Creus-Costa, MD, Poster# <FONT
STYLE="white-space:nowrap">P-1186)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Friday, October</B><B></B><B>&nbsp;18, <FONT STYLE="white-space:nowrap">12:15-1:30</FONT> pm PT:</B> The burden of
respiratory syncytial virus among Brazilian infants (BONSAI study): preliminary results (Sanofi, presented by Manoel Ribeiro, MD, PhD, Poster# <FONT STYLE="white-space:nowrap">P-1199)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt"><B>Saturday, October</B><B></B><B>&nbsp;19, <FONT STYLE="white-space:nowrap">12:15-1:30</FONT> pm PT:</B> Nirsevimab
in Patient Samples Does Not Interfere with Respiratory Syncytial Virus (RSV) Detection by Commercially Available Rapid Antigen Tests (AstraZeneca, presented by Sarah R. Sincero, BSc, Poster# <FONT STYLE="white-space:nowrap">P-2179)</FONT>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Verdana; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g871391img02.jpg" ALT="LOGO" STYLE="width:0.708333in;height:0.189583in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About RSV </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">RSV is a highly contagious virus that can lead to serious respiratory illness for infants.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Two out of three
infants are infected with RSV during their first year of life and almost all children are infected by their second birthday.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP>&nbsp;RSV is the most common cause of lower respiratory tract
disease, including bronchiolitis and pneumonia, in infants.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> It is also a leading cause of hospitalization in infants worldwide, with most hospitalizations for RSV occurring in healthy infants
born at term.<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">4-7</FONT></SUP> Globally, in 2019, there were approximately 33&nbsp;million cases of acute lower respiratory infections leading to more than 3&nbsp;million
hospitalizations in children younger than 5 years.<SUP STYLE="font-size:75%; vertical-align:top">8</SUP> <FONT STYLE="white-space:nowrap">RSV-related</FONT> direct medical costs, globally &#151; including hospital, outpatient and <FONT
STYLE="white-space:nowrap">follow-up</FONT> care &#151; were estimated at <FONT STYLE="font-family:Times New Roman">&#128;</FONT>4.82&nbsp;billion in 2017.<SUP STYLE="font-size:75%; vertical-align:top">9</SUP> </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #b2b2b2">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About Beyfortus </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">Beyfortus
(nirsevimab) is the first immunization designed for all infants for protection against RSV disease through their first RSV season, including for those born healthy at term or preterm, or with specific health conditions. Beyfortus is also designed to
protect children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">As a long-acting antibody provided directly
to newborns and infants as a single dose, Beyfortus offers rapid protection to help prevent lower respiratory tract disease caused by RSV without requiring activation of the immune system. Beyfortus administration can be timed to coincide with the
RSV season. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">Beyfortus has been approved for use in the European Union, the US, China, Japan, and many other countries around the world. Special designations to
facilitate expedited development of Beyfortus were granted by several regulatory agencies, including Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products
Administration;&nbsp;Breakthrough Therapy&nbsp;Designation&nbsp;and Fast Track Designation from the US Food and Drug Administration; access granted to the European Medicines Agency (EMA)&nbsp;PRIority&nbsp;MEdicines&nbsp;(PRIME) scheme and EMA
accelerated assessment; Promising Innovative Medicine designation by the UK Medicines and Healthcare products Regulatory Agency; and Beyfortus has been named &#147;a medicine for prioritized development&#148; under the Project for Drug Selection to
Promote New Drug Development in Pediatrics by the Japan Agency for Medical Research and Development. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #b2b2b2">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About Sanofi
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team,
across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Evan Berland</B> | +1 215 432 0234 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Nicolas Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <FONT
STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Timothy Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Thomas Kudsk Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 | <FONT
STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Arnaud Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Keita Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Tarik Elgoutni </B>| + 1 617 710 3587 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT
STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #b2b2b2">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g871391img02.jpg" ALT="LOGO" STYLE="width:0.708333in;height:0.189583in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Verdana; ">2/3</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify"><B>Sanofi forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in
the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify">All trademarks mentioned in this press release are the property of the Sanofi group. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><B>References: </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">U.S. Centers for Disease Control and Prevention. RSV in Infants and Young Children.
https://www.cdc.gov/rsv/high-risk/infants-young-children.html. Accessed August 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Walsh EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clinics in Chest Medicine. <FONT
STYLE="white-space:nowrap">2017;38(1):29-36.</FONT> <FONT COLOR="#7a00e6"><U>https://doi.org/10.1016/j.ccm.2016.11.010</U></FONT>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">R K. Respiratory Syncytial Virus Vaccines. Plotkin SA, Orenstein WA, Offitt PA, Edwards KM, eds Plotkin&#146;s
Vaccines 7th ed Philadelphia. 2018;7th ed. <FONT STYLE="white-space:nowrap">Philadelphia:943-9.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. <I>The Pediatric
infectious disease journal.</I> <FONT STYLE="white-space:nowrap">2002;21(7):629-32.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs
of full-term and preterm infants. Journal of Perinatology: official journal of the California Perinatal Association. <FONT STYLE="white-space:nowrap">2016;36(11):990-6.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016.
<I>Pediatrics</I>. 2020;146:e20193611. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among
Children Aged &lt;2 Years in the United States, <FONT STYLE="white-space:nowrap">2014-15.</FONT> <I>J Pediatric Infect Dis Soc</I>. <FONT STYLE="white-space:nowrap">2020;9:587-595.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to
respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. <I>Lancet.</I> 2022;399:92047&#150;64. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Verdana; " ALIGN="justify">Zhang S, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young
Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. <I>J Infect Dis</I>. 2020;222(Suppl <FONT STYLE="white-space:nowrap">7):S680-687.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Verdana; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g871391img02.jpg" ALT="LOGO" STYLE="width:0.708333in;height:0.189583in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d871391dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Verdana"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g871391img01.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Sanofi in discussions to sell a controlling stake in Opella </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><B>Paris, October</B><B></B><B>&nbsp;11, 2024. </B>Sanofi today announces that the company has entered into negotiations with CD&amp;R for the
potential sale of a 50% controlling stake in Opella, its consumer healthcare business. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><FONT COLOR="#0d0d0d">Should these discussions lead to a
positive outcome, any agreement would be subject to the completion of the necessary social processes. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><FONT COLOR="#0d0d0d">Further
updates on the potential separation of Opella will be provided in due course, when a decision is made. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><FONT COLOR="#0d0d0d">Headquartered
in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> manufacturing sites and four research and innovation centers. With
a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world&#146;s third-largest company in the over the counter and vitamins, minerals, and supplements market, serving more than half a
billion consumers worldwide. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><FONT COLOR="#0d0d0d">Opella&#146;s journey to independence aligns with Sanofi&#146;s strategy to focus on
innovative medicines and vaccines. Opella already operates today as a standalone business unit within Sanofi, with dedicated resources for R&amp;D, production, digital, and with its own sustainability roadmap. Opella is now a leading company in its
sector, focused on brands and consumer-oriented, and achieved 6.3% sales growth at constant exchange rates in 2023. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #b2b2b2">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About Sanofi
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives.
Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people
globally, while putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Nicolas Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>L&eacute;o Le Bourhis </B>|&nbsp;+ 33 6 75 06 43 81 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Evan Berland</B> | +1 215 432 0234 | <FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Thomas Kudsk Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 | <FONT
STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Arnaud Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Keita Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="justify"><B>Tarik Elgoutni </B>| + 1 617 710 3587 | <FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:9pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #b2b2b2">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g871391img02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Verdana; ">1/2</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions, and expectations with respect
to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;,
&#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148;, &#147;potential&#148;, &#147;outlook&#148;, &#147;guidance&#148; and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of
Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the
uncertainties inherent in negotiations, including the ability to negotiate and reach an agreement on the terms, conditions, and modalities of a possible transaction, to conclude and complete a possible transaction and/or obtain regulatory
clearances, and other risks associated with volatile economic, market and political conditions. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi,
including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31,
2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify">All trademarks mentioned in this press release are the property of the Sanofi group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Verdana; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g871391img02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g871391img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871391img01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\L_ /A_[=-'Y]W,WEVUOG&]NY)[ =S]/6@#YAUGXH^+M>NFEN;] "<K'';H
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M%?!#_DKFB_2;_P!$O0![-^T+_P DU3_K^B_]!>@#SG]G#_D?=1_[!K_^C(Z
M/IV@#X9\7_\ (ZZ]_P!A"?\ ]&-0!]B:5IT.K_#FQTVX&8;O2XX7^C1 '^=
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@_9\C>^DQXE8*9#Q]CY SZ[Z /=_[%A_YZO\ I0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g871391img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871391img02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M,6FZ=8?L_?%>"QL+*R@E\4?%+S8;2U@MHI-EAY"^9'#&JOM@CCC&0<(BKT
M_7?&?$8C$<397+$5ZE>4<ERY)U)RFU>-23LY-M7DW)]VV]VSZCBVI4J9CAW4
MG*;6$P]G)M]&^M^K;]6>2?L5>#O"-S^Q[\0]!N/"OAR?0]0\1>,);_1IM#TR
M72KZ1-#T;9)>:<]J;>Y=?)APTD;$>4F/NC'Y$?+GY._LO^ ? FK_ +1NGZ5J
MW@KPEJFEIK5Z$TW4?#FCWM@@AG<Q!;.YLWB785&W"?+@8QB@#]=?BGH>BM_P
M4,_9^U!M'TMM0LO [0V=\VGVAO+2&/3_ !^D<5M<F'S((U1W4*C* '8 8)H
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J#7AVV^"G@J&WT#18(4'B'9%#I5C%&F[Q7KKMMC2 *N79B<#DDGJ: /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
